Program Description
While small cell lung cancer (SCLC) accounts for only 14% of all lung cancer cases, it is typically aggressive and difficult to treat. The quick development of resistance to chemotherapy combined with limited second-line treatment options presents significant challenges for patients with SCLC and complicates medication management. This program will examine the role of delta-like ligand 3 (DLL3)-targeted therapies including their mechanisms of action, efficacy data, and adverse effect profiles. Oncology pharmacists must be informed about these investigational and emerging treatment regimens as well as updated guideline recommendations to support appropriate and effective treatment protocols for SCLC. This webinar will present oncology pharmacists with actionable strategies to not only prepare for additional second-line treatment options in SCLC but also address medication-related toxicities to facilitate comprehensive patient care.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: November 15, 2024
Expiration date: November 15, 2025
Time to complete activity: 1.0 hour
Learner level: Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the mechanisms of action and safety profiles of new and emerging DLL3-targeted therapies for small cell lung cancer (SCLC).
- Describe emerging strategies to utilize DLL3-targeted therapies in the treatment of SCLC and how recent trial evidence may inform evolving treatment paradigms.
- Illustrate approaches to identify, prevent, and manage treatment-associated adverse effects of DLL3-targeted therapies.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
